Advances on the target antigens and immunosuppressive treatment in membranous nephropathy
10.3760/cma.j.cn441217-20231017-01027
- VernacularTitle:膜性肾病靶抗原和免疫抑制治疗的研究进展
- Author:
Yishu WANG
1
;
Yi WANG
;
Xiaoyan MA
;
Jun WANG
;
Shuchen MA
;
Na LIU
Author Information
1. 同济大学附属东方医院肾内科，上海 200120
- Keywords:
Glomerulonephritis, membranous;
Antigen;
Diagnosis;
Immunosuppressive agents
- From:
Chinese Journal of Nephrology
2024;40(5):418-425
- CountryChina
- Language:Chinese
-
Abstract:
Membranous nephropathy (MN) is a type of glomerular disease characterized by diffuse thickening of glomerular basement membrane with subepithelial immune complex deposition, and traditional diagnosis of MN mainly relies on the pathological results of renal biopsy. In recent years, the emergence of biomarkers related to MN such as phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A has changed the diagnosis and treatment mode of MN, providing a new basis for the diagnosis, treatment and prognosis of MN. MN patients with positive specific target antigens exhibit different clinical manifestations and prognoses. Specific target antigens can not only guide diagnosis, but also has predictive value for prognosis. Immunosuppressive therapy is a common treatment for idiopathic MN patients, and the emergence of novel medications such as biologics represents a advance in the treatment of MN, providing a broader array of options for managing the condition. Conversely, the treatment approach for secondary MN primarily targets the management of the primary disease. Based on multiple and new literature, we reviewed the researches progress of target antigens and immunosuppressive therapy related to MN, so as to provide references for clinical diagnosis and treatment of MN.
